• Founded in

    2017

  • Company Industry

    Software Development

  • Headquarters

    180 Varick Street, New York, - 10014, New York, US

About us

Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning predictions to enable critical decision-making. We currently work with several of the largest global pharmaceutical companies as well as mid-size and smaller biotechnology companies. Diseases will impact nearly every individual. At Intelligencia AI, we work to make a difference.
  • Funding Round/Series

    Seed Round

  • Funding Amount

    $ 3.5M

  • Latest Funding Date

    12, 2018

  • Investors

    Synetro Group, Velocity.Partners, Big Pi, Bantam Group, Amit Singhal, Amit Singhal, Dave Baggett